Skip to main content

Table 2 Antiviral activity IC50 of BFFI in PBMC assays

From: Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1

HIV Virus

Tropism

BFFI*

CCR5mAb*

T-2635*

NLBal

R5

0.13 ± 0.06

0.23 ± 0.09

0.58 ± 0.40

JRCSF

R5

0.60 ± 0.13

1.16 ± 0.45

0.29 ± 0.10

YU2.c

R5

0.07 ± 0.016

0.24 ± 0.09

0.26 ± 0.12

92US715

R5

0.34 ± 0.19

0.96 ± 0.39

0.55 ± 0.30

CC1/85

R5

0.67 ± 0.36

1.12 ± 0.34

1.41 ± 0.31

Mean

R5

0.36 ± 0.27

0.62 ± 0.47

0.74 ± 0.47

p-value vs. BFFI

 

0.0800

0.0410

NL4-3

X4

>100

>100

0.70 ± 0.31

89.6

R5X4

>100

>100

0.91 ± 0.12

  1. * Results are IC50 ± SD (nM) from 3 or more independent experiments.
  2. The log10 values of the IC50 for all three drugs and R5 virus isolates were compared using a two-way ANOVA model including terms of drug and virus followed by post-hoc comparison using Fisher's LSD test
Back to article page

Virology Journal

ISSN: 1743-422X